Abstract 66P
Background
The phenomenon of intratumoral morphological heterogeneity is associated with both the progression of the disease and chemosensitivity and chemoresistance. However, there are very few data about the microenvironment heterogeneity near morphological structures in breast cancer patients of various molecular subtypes. This phenomenon may underlie the failure of tumor-infiltration lymphocytes as a prognostic factor in luminal forms of breast cancer.
Methods
152 patients with IC NST (T1–3N0–2M0) aged 29 to 75 years were enrolled in the study. The molecular subtype was determined using immunohistochemical analysis of the expression of estrogen and progesterone receptors, Ki-67 and Her2/neu. TILs were assessed in accordance with the recommendations of the International TILs Working Group
Results
It was shown that TILs near the various morphological structures is heterogeneous only in luminal Her2-negative patients. In addition, was found that the development of distant metastases and worse metastatic-free survival in this cohort of patients is associated with a high (more than 5%) TILs near solid structures and also depended on Ki-67 level.
Conclusions
TILs near solid structures is a potential prognostic factor for the development of distant metastasis in the luminal Her2-negative and Ki-67 level less 20% subtype of IC NST. The study was supported by the Russian Science Foundation (grant #20-75-10033).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the Russian Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session